Tevogen

Tevogen Bio Holdings’ Board of Directors is evaluating a potential special cash dividend for shareholders. This consideration comes amid significant advancements in their novel immunotherapy platform targeting cancers and infectious diseases. While details remain undisclosed, the move suggests a strong financial position or a strategy to reward investors. Positive clinical trial results for their investigational drug, TVGN 466, could underpin this decision.